Imaris maps TB lung lesions precisely in primate studies

Tuberculosis remains a disease defined by how it affects the lungs, but following individual spots of inflammation inside the lung over time is technically challenging. Researchers led by corresponding author Vitaly V. Ganusov set out to test whether a modern image-analysis platform could reliably identify and track those spots in animals exposed to Mycobacterium tuberculosis. The team focused on sites that show up on PET scans—areas where inflammation and metabolic activity concentrate—and asked whether the software called Imaris could be used to extract meaningful, measurable information from those PET-defined lesions. By comparing what Imaris produced with values from an established imaging package, the group aimed to bring a more rigorous, data-rich approach to following the course of lung lesions. The study centered on non-human primates exposed to Mycobacterium tuberculosis, using PET imaging as the basis for identifying sites of inflammation, and then applying Imaris to analyze and export details about each identified lesion.

The core technical comparison in this work was between two image-analysis outputs. Individual lesion maximum SUV (standardized uptake value) was determined using Invicro VivoQuant, and those values were compared with maximum intensity measurements produced by Imaris. The researchers report an excellent correlation between an individual lesion’s maximum SUV from Invicro VivoQuant and its maximum intensity as determined by Imaris, suggesting that Imaris can reproduce a key PET-derived metric. Beyond that direct comparison, Imaris provides a wealth of additional information for each identified lesion: volume, location, shape, surface area, and other measurable features. Each lesion analyzed in Imaris can also be exported in Virtual Reality file format (.wrl), enabling detailed and rigorous analyses of how features of these PET-defined lesions evolve over time and how they correlate with the outcome of infection and/or treatment.

Taken together, these findings point to a practical workflow for researchers who want to go beyond single-number summaries and build a richer picture of lung disease in experimental tuberculosis. The excellent correlation with Invicro VivoQuant gives confidence that Imaris-derived measures align with established PET metrics, while the extra geometric and spatial details open new possibilities for tracking lesion progression or regression. The ability to export lesions in .wrl format means teams can visually inspect, quantify, and compare lesions in immersive or detailed 3D environments, which may aid studies that seek to link lesion characteristics with how infections evolve or how well treatments work. While the abstract presents these results as a proof of utility rather than a definitive clinical tool, the approach gives researchers a more rigorous and flexible way to analyze PET-defined lung inflammation in Mycobacterium tuberculosis–exposed non-human primates.